Search Results - "Minatoyama, Shuhei"

Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy by Inomata, Minehiko, Minatoyama, Shuhei, Takata, Naoki, Hayashi, Kana, Hirai, Takahiro, Seto, Zenta, Tokui, Kotaro, Taka, Chihiro, Okazawa, Seisuke, Kambara, Kenta, Imanishi, Shingo, Miwa, Toshiro, Matsuyama, Kei, Hayashi, Ryuji, Matsui, Shoko, Tobe, Kazuyuki

“…Combined therapy with immune checkpoint inhibitors plus platinum doublet chemotherapy has a survival advantage over platinum doublet chemotherapy in patients…”
Get more information

Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report by Hirai, Takahiro, Inomata, Minehiko, Minatoyama, Shuhei, Hashizume, Moe, Takata, Naoki, Hayashi, Kana, Seto, Zenta, Tokui, Kotaro, Taka, Chihiro, Okazawa, Seisuke, Kambara, Kenta, Imanishi, Shingo, Miwa, Toshiro, Hayashi, Ryuji, Tanaka, Shinichi, Noguchi, Akira, Sato, Tsutomu

“…Immune checkpoint inhibitors can induce immune-related adverse events in various organs, thus careful observation is required. A 69-year-old man was diagnosed…”
Get full text

Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression by Inomata, Minehiko, Minatoyama, Shuhei, Takata, Naoki, Hayashi, Kana, Hirai, Takahiro, Seto, Zenta, Tokui, Kotaro, Taka, Chihiro, Okazawa, Seisuke, Kambara, Kenta, Imanishi, Shingo, Miwa, Toshiro, Hayashi, Ryuji, Matsui, Shoko, Tobe, Kazuyuki

“…In epidermal grow th factor receptor (EGFR) -mutant non-small cell lung cancer (NSCLC) with negative or low programmed death ligand-1 (PD-L1) expression, the…”
Get full text